Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Italy Peptide Receptor Radionuclide Therapy (PRRT) Market – Insights

The market opportunities for key players to enter into this market are high owing to less competition and increasing demand for peptide receptor radionuclide therapy in the Italy market. Moreover, increasing incidence of cancer in Italy is directly contributing to demand for PRRT therapy. These factors are creating growth opportunities for companies to focus on research and development of new drugs. As per the Italian Association of Medical Oncology’s report, in April 2019, 71,000 new cases were diagnosed with new additional cancer cases.

The Italy Peptide Receptor Radionuclide Therapy (PRRT) Market was valued at US$ 3.6 million in 2019, and is expected to witness a CAGR of 9.2%over the forecast period (2019 – 2027).

Italy Peptide Receptor Radionuclide Therapy (PRRT) Market Share (%) Analysis, By Drug Type, 2019

Italy Peptide Receptor Radionuclide Therapy  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Increasing incidence of pancreatic cancer, as well as availability of reimbursement for cancer drug is another factor contributing to the market growth.

Increasing incidence of pancreatic cancer in Europe region is expected to support growth of the market over the forecast period. For instance, according to United European Gastroenterology report in Europe region, there was a 5% increase in the number of pancreatic cancer cases during the years 1990 to 2016.

The European Medicines Agency (EMA) plays a central role in facilitating development and authorization of medicines for rare diseases, which are termed as ‘orphan medicines’. In Italy, prices of ODs (Orphan Drugs) and reimbursement by the National Health Service is set through negotiation between the Italian Medicines Agency (AIFA), and pharmaceutical companies. Reimbursement of 38% is available for ODs in Italy which includes peptide receptor radionuclide therapy (PRRT).

Italy Peptide Receptor Radionuclide Therapy (PRRT) Market - Restraints

High cost associated with cancer treatment, which include diagnosis and therapeutic treatment, is a major factor that is expected to restrain growth of the market. For instance, as per the Economist Intelligence Unit Limited’s 2016 report, lung cancer treatment cost has become a burden on the economy in Italy. In 2013, it was estimated that total cost for treatment of lung cancer reached around US$ 18.31 billion.

Currently, only one approved PRRT drug is available in the Italy market, and is used in the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumor (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. Therefore, lack of availability of different drugs is another major factor restraining growth of the market.

Moreover, high cost of treatment is expected to restrain growth of the market. For instance, Novartis Company’s drug, Lutathera, is priced at US$ 99,900 for a full course of treatment comprising four infusions.

Italy Peptide Receptor Radionuclide Therapy (PRRT) Market Value (US$ Mn) & Y-o-Y Growth (%), 2016-2027

Italy Peptide Receptor Radionuclide Therapy  | Coherent Market Insights

 Source: Coherent Market Insights Analysis (2019)

Key player operating in the Italy Peptide Receptor Radionuclide Therapy (PRRT) Market is Novartis International AG.

Peptide receptor radionuclide therapy (PRRT) is a type of molecular therapy, also known as radioisotope therapy that is used for treating neuroendocrine tumors. In this therapy, a peptide similar to the natural hormone is combined with radioactive material such as Yttrium and Lutetium, to produce radionuclide which is then injected into the patient’s body. This combination binds to the neuroendocrine tumors in the body. It is a cell targeting type of therapy since it delivers a high dose of radiation directly to the tumor cells.

Market Dynamics

Rising number of cancer cases in Italy is expected to drive the Italy peptide receptor radionuclide therapy (PRRT) market growth during the forecast period. For instance, as per data published by the Epidemiology Unit, Agency for Health Protection of Milan, Corso Italia, in 2012- 2015, 3,803 patient  diagnosed with colorectal cancer. Cancer patients in the age group below 50 years accounted for 22.25%, of the total cancer cases that were reported and patients in the age group of 50 to 64 years accounted for 17.65%, and patients over the age of 65 accounted 20.80%.

Furthermore, according the WHO, in 2018, around 43,837 cases of prostate cancer were reported, which contributed around 10% of the total cancer cases recorded in Italy.

However, side effects associated with peptide receptor radionuclide therapy may negatively impact growth of the peptide receptor radionuclide therapy market. The side effects occur on the body part which is treated with radiation. Some of the common side effects faced by patients undergoing radiation therapy are nausea, vomiting, abdominal discomfort or pain, and in some cases, temporary hair loss and sub-acute hematology toxicity. Hence, this may hamper the Italy peptide receptor radionuclide therapy market growth.

Key features of the study:

  • This report provides in-depth analysis of the Italy peptide receptor radionuclide therapy (PRRT) market, market size (US$ Mn), and compound annual growth rate (CAGR (%) for the forecast period, 2019-2027, considering 2018 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles the key player in the Italy peptide receptor radionuclide therapy (PRRT) market based on the following parameters: company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • The key player covered as a part of this study is Novartis International AG
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The Italy peptide receptor radionuclide therapy (PRRT) market report caters to various stakeholders in this industry, which include investors, product manufacturers, distributors, and suppliers for Italy Peptide Receptor Radionuclide Therapy (PRRT) Market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Italy Peptide Receptor Radionuclide Therapy (PRRT) Market, by Drug Type:
    • Lutetium (Lu-177)-based
    • Yttrium (Y-90)-based
  • Italy Peptide Receptor Radionuclide Therapy (PRRT) Market, by Indication
    • Gastroenteropancreatic Neuroendocrine Tumor
  • Italy Peptide Receptor Radionuclide Therapy (PRRT) Market, by Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
  • Company Profiles
    • Novartis International AG *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Indication
      • Market Snippet, By Distribution Channel
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Regulatory Scenario
    • Reimbursement Scenario
    • PEST Analysis
    • Key Developments
    • Epidemiology
  4. Italy Peptide Receptor Radionuclide Therapy (PRRT) Market, By Drug Type, 2019 – 2027, (US$ Million)
    • Introduction
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Lutetium (Lu-177)-based       
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027 , (US$ Million)
    • Yttrium (Y-90)-based
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027 , (US$ Million)
  5. Italy Peptide Receptor Radionuclide Therapy (PRRT) Market, By Indication, 2019 – 2027, (US$ Million)
    • Introduction
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Gastroenteropancreatic Neuroendocrine Tumor      
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027 , (US$ Million)
  6. Italy Peptide Receptor Radionuclide Therapy (PRRT) Market, By Distribution Channel, 2019 – 2027, (US$ Million)
    • Introduction
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027 , (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027 , (US$ Million)
  7. Competitive Landscape
    • Company Profiles
      • Novartis International AG.*
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
  8. Section
    • References
    • Research Methodology         
    • About Us and Sales Contact

*Browse 9 market data tables and 12 figures on “Peptide Receptor Radionuclide Therapy (PRRT)” – Italy forecast to 2027”

Frequently Asked Questions

The Italy peptide receptor radionuclide therapy (PRRT) market is estimated to account for US$ 3.6 million in 2019.
The Italy peptide receptor radionuclide therapy (PRRT) market is expected to exhibit a CAGR of 9.2% over the forecast period (2019-2027).
Major player operating in the Italy peptide receptor radionuclide therapy (PRRT) market include Novartis International AG
High cost associated with cancer treatment and shortage of different drugs for the treatment of tumors are the major factors that are expected to hamper growth of the market over the forecast period.
The rising incidence of pancreatic cancer, coupled with availability of reimbursement for cancer drug are the major factors that are expected to drive growth of the market over the forecast period.
The Italy peptide receptor radionuclide therapy (PRRT) market is estimated to reach US$ 7.2 million by 2027.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner